Anna Vulpetti has over 25 years of experience in drug discovery in Pharma, at Pharmacia & Upjohn, Pharmacia, Pfizer, and since 2006 at Novartis. She is an Associate Director in the Global Discovery Chemistry department at Novartis with experience from hit finding technologies to hit-to-lead and late-stage optimization. By working interdisciplinary across different disease areas, she impacted multiple pipeline projects through molecular designs, knowledge in medicinal chemistry and structural chemistry.
Anna Vulpetti has co-authored more than 80 peer-reviewed scientific papers and many patents.

Senior Director at AstraZeneca responsible for Structural Biology with crystallography, cryoEM and computational structural biology teams. Joined AZ 11 years ago from Pfizer having previously completed a D. PHIL at the University of Oxford.
Responsible for and passionate about the application of structural biology across the AZ portfolio; large molecules, small molecules, vaccines, and other novel modalities. Early Discovery Project lead for several oncology projects.